| NCT02855944 | III | Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy) | ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | View Drugs | Colorado, Georgia |
| Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
| NCT02091141 | IIa | Advanced solid tumors with ALK mutations or high TMB | My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents | View Drugs | Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin |
| Alectinib | ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802 | ALK kinase inhibitor | | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells |
|
| NCT02584478 | IIa | Recurrent ovarian cancer | A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | View Drugs | California, Florida, Louisiana, Texas |
| Anlotinib | AL3818 | VEGFR2/3 kinase inhibitor | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT02419417 | IIa | Platinum resistant or refractory ovarian cancer with BRCA1/2 mutations | A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies | View Drugs | California, Colorado, Oregon, South Carolina |
| BMS-986158 | BET inhibitor BMS-986158 | BET inhibitor | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02502266 | II/III | Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer | A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) | View Drugs | Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin |
| Cediranib | Recentin, Cediranib maleate, AZD2171 | VEGFR1-3 kinase inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT02485990 | II | Platinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane) | An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | View Drugs | Maryland |
| Olaparib | AZD2281, Lynparza | PARP inhibitor | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
| NCT02568267 | II | Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | View Drugs | Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington |
| Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101 | ALK, TRK, ROS1 kinase inhibitor |
|
| NCT01953926 | II | Advanced solid tumors with activating HER2 mutations | An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification. | View Drugs | Arizona, California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin |
| Neratinib | HKI-272, PD272 | EGFR, HER2, HER4 kinase inhibitor |
|
| NCT02203513 | II | Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer | View Drugs | Maryland |
| Prexasertib | checkpoint kinase 1 inhibitor LY2606368, LY2606368 | Chk1/2 inhibitor |
|
| NCT02312245 | II | Platinum resistant or refractory ovarian cancer | Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers | View Drugs | Arizona, Florida, Minnesota |
| Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor |
|
| NCT01037790 | II | Advanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterations | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | View Drugs | Pennsylvania |
| Palbociclib | Ibrance, PD0332991, PD-0332991 | CDK4/6 inhibitor |
|
| NCT02272998 | II | Advanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations | Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1) | View Drugs | Ohio |
| Ponatinib | multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534 | Multi-targeted kinase inhibitor |
|
| NCT02079740 | II | Advanced solid tumors with KRAS or NRAS mutations (in expansion) | An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors | View Drugs | Massachusetts |
| Navitoclax | Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263 | Bcl-2, Bcl-XL, and Bcl-w inhibitor | | Trametinib | TMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist | MEK1/2 inhibitor |
|
| NCT01827384 | II | Advanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53 | Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors | View Drugs | Colorado, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Everolimus | Zortress, RAD001, Certican, Afinitor | mTOR inhibitor | | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | | Trametinib | TMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist | MEK1/2 inhibitor | | Veliparib | ABT-888 | PARP inhibitor |
|
| NCT02554812 | II | Advanced solid tumors (in ovarian expansion) | A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies | View Drugs | California, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | PD-0360324 | anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 | CSF1R antagonist and tumor-associated macrophage inhibitor | | PF-04518600 | anti-OX40 antibody PF-04518600 | Stimulates OX40 to increase T cell activation and immune response |
|
| NCT02832167 | II | Advanced solid tumors | An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies | View Drugs | Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia |
| Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02693535 | II | Ovarian Expansion for BRCA MUT1/2 or CDKN2A loss or mutation or Advanced solid tumors with molecular alterations in ALK, ROS1, MET, CDK4, CDK6, CSF1R, PDGFR, VEGFR, mTOR, TSC, ERBB2, BRAFV600E/D/K/R, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, ATM, POLD, POLE, high TMB, MSI high) | Targeted Agent and Profiling Utilization Registry (TAPUR) Study | View Drugs | Alabama, Arizona, California, Florida, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington |
| Cetuximab | Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 | EGFR antagonist | | Cobimetinib | Cotellic, GDC-0973, XL518 | MEK1 inhibitor | | Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor | | Dasatinib | BMS-354825, Sprycel | SRC and bcr-abl kinase inhibitor | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Olaparib | AZD2281, Lynparza | PARP inhibitor | | Palbociclib | Ibrance, PD0332991, PD-0332991 | CDK4/6 inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | | Sunitinib | Sutent, Sunitinib malate | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | | Temsirolimus | CCI-779, Torisel | mTOR inhibitor | | Trastuzumab | HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin | HER2 antagonist | | Vemurafenib | RO5185426, PLX4032, Zelboraf | BRAF kinase inhibitor |
|
| NCT02465060 | II | Advanced solid tumors with alterations in ALK, cKIT, EGFR, ERBB2 AMP, FGFR1-3, FGFR1-3 AMP, GNAQ, GNA11, MET, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, ROS1, SMO, TSC1/2 | Molecular Analysis for Therapy Choice (MATCH) | View Drugs | Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming |
| Afatinib | BIBW 2992 MA2, Gilotrif, Afatinib dimaleate | EGFR, HER2, HER4 kinase inhibitor | | Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | | Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor | | Erdafitinib | pan-FGFR tyrosine kinase inhibitor JNJ-42756493 | pan-FGFR kinase inhibitor | | Larotrectinib | Trk inhibitor LOXO-101 | Pan-Trk kinase inhibitor | | Osimertinib | Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib | EGFR kinase inhibitor | | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | | Sapanisertib | TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128 | TORC1/2 kinase inhibitor | | Sunitinib | Sutent, Sunitinib malate | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | | Trametinib | TMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist | MEK1/2 inhibitor | | Trastuzumab | HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin | HER2 antagonist | | Vismodegib | Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 | Smoothened antagonist |
|
| NCT02628067 | II | Advanced solid tumors with high MSI | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | View Drugs | California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New Mexico, Texas |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02576444 | II | Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations | A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors | View Drugs | Connecticut, Massachusetts, Ohio, Tennessee |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | | Capivasertib | Akt inhibitor AZD5363 | pan-AKT inhibitor | | Ceralasertib | AZD6738 | ATR kinase inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT01851369 | II | Advanced solid tumors and granulosa cell ovarian cancer (in expansion) | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | View Drugs | Maryland |
| methoxyamine | TRC102 | Base excision repair inhibitor | | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent |
|
| NCT02364713 | II | Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity) | A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer | View Drugs | Arizona, Florida, Minnesota |
| MV-NIS | oncolytic measles virus encoding thyroidal sodium iodide symporter | Induces immune response and tumor cell lysis |
|
| NCT01697527 | II | Advanced NY-ESO-1+ solid tumors | Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies | View Drugs | California |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | | NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL | anti-NY-ESO-1 TCR gene-engineered lymphocytes | Immune response against cancer expressing NY-ESO-1 | | NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine | | Immune response against cancer expressing NY-ESO-1 |
|
| NCT02834013 | II | Advanced ovarian germ cell, mucinous, squamous cell, or adenocarcinoma | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | View Drugs | Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02873975 | II | Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations | A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency | View Drugs | Massachusetts |
| Prexasertib | checkpoint kinase 1 inhibitor LY2606368, LY2606368 | Chk1/2 inhibitor |
|
| NCT02900560 | II | Platinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease) | Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | View Drugs | California, Maryland, Minnesota |
| Oral Azacitidine | CC-486 | DNA methylation inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02843165 | II | Advanced solid tumors with lesion treatable with radiotherapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | View Drugs | California |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Radiation Therapy | Radiotherapy, Irradiation | |
|
| NCT03026062 | II | Platinum resistant or refractory ovarian cancer | Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer | View Drugs | Texas |
| Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
| NCT03093155 | II | Platinum resistant, refractory or persistent ovarian cancer | A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | View Drugs | Connecticut, Maryland |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Ixabepilone | Azaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B, Ixempra | Microtubule stabilizer/mitotic inhibitor |
|
| NCT02587598 | II | Advanced solid tumors (in expansion) | A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies | View Drugs | Arizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, Ohio, Oklahoma, Tennessee, Texas, Wisconsin |
| Azacytidine | azacitidine, Vidaza, Mylosar, 5-AZC | DNA methylation inhibitor | | INCB053914 | pan-PIM inhibitor INCB053914 | PIM1, 2, 3 inhibitor |
|
| NCT02920996 | II | Advanced solid tumors with NTRK1-3 rearrangements | A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements | View Drugs | Massachusetts |
| Merestinib | c-Met inhibitor LY2801653, LY2801653 | Multi-targeted RTK inhibitor |
|
| NCT03113487 | II | Platinum resistant ovarian cancer | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | View Drugs | California |
| p53MVA | Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53 | Immune response against p53 tumor antigen | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03212274 | II | Advanced solid tumors with IDH1 or IDH2 mutations | A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | View Drugs | California, Connecticut, District of Columbia, Kentucky, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin |
| Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT03253679 | II | Advanced solid tumors with CCNE1 AMP | A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification | View Drugs | California, Colorado, District of Columbia, Florida, Kentucky, New York, North Carolina, Pennsylvania, Texas |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor |
|
| NCT03274661 | II | Advanced solid tumors | Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency | View Drugs | Florida |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03284385 | II | Advanced solid tumors with SETD2 deficiency | A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies | View Drugs | California, District of Columbia, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor |
|
| NCT03300843 | II | Advanced solid tumors (with resectable tumor) | A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | View Drugs | Maryland |
| Peptide loaded dendritic cell vaccine | | Anti-tumor immune response |
|
| NCT03310879 | II | Advanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplifications | A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | View Drugs | Massachusetts |
| Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor |
|
| NCT03348631 | II | Recurrent or persistent endometrioid/clear cell ovarian cancer | A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma | View Drugs | Alaska, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Virginia, Washington, Wisconsin, Wyoming |
| Tazemetostat | histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438 | EZH2 histone methyltransferase inhibitor |
|
| NCT03355976 | II | Recurrent clear cell ovarian cancer | BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | View Drugs | Rhode Island |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03147976 | II | Advanced solid tumors with MET over-expression or mutation | A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) Mutations | View Drugs | California |
| AMG 337 | | c-Met kinase inhibitor |
|
| NCT03395080 | II | Platinum resistant or refractory ovarian cancer | A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer | View Drugs | Alabama, Arizona, Florida, Illinois, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin |
| DKN-01 | DKK1-neutralizing monoclonal antibody DKN-01 | Dickkopf-1 (DKK1) antagonist | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT03428802 | II | Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | View Drugs | New Jersey |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT01876511 | II | Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB | Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | View Drugs | California, Maryland, New York, Ohio, Oregon, Pennsylvania |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03570619 | II | Advanced solid tumors with CDK12 alterations | IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | View Drugs | Florida, Michigan, New York |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03565991 | II | Advanced solid tumors with BRCA1/2 or ATM mutations | A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors | View Drugs | California, Georgia, Louisiana, Massachusetts, Missouri, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor |
|
| NCT03579316 | II | Recurrent ovarian cancer (PD on or after prior PARP inhibitor) | A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition | View Drugs | Massachusetts, Texas |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT03610490 | II | Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | View Drugs | Texas |
| MDA-TIL | autologous tumor-infiltrating lymphocytes MDA-TIL | Anti-tumor immune response |
|
| NCT03651271 | II | Recurrent ovarian cancer with high MSI | An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer | View Drugs | California, Massachusetts, New York, Texas |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03668119 | II | Advanced solid tumors with high TMB | A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | View Drugs | California, Colorado, Illinois, Minnesota, New York, North Carolina, Oregon, Tennessee, Texas |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03587311 | II | Platinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancer | A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer | View Drugs | Missouri, Ohio |
| Anetumab ravtansine | BAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343 | ADC: anti-mesothelin + microtubule destabilizer (DM4) | | Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT03682289 | II | Recurrent ovarian cancer | Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies | View Drugs | California |
| Ceralasertib | AZD6738 | ATR kinase inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT03693014 | II | Advanced solid tumors with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | View Drugs | New Jersey, New York |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Radiation Therapy | Radiotherapy, Irradiation | |
|
| NCT03718091 | II | Advanced solid cancer with ATM truncation mutations or other HR gene mutations | A Phase II Study of M6620 (VX-970) in Selected Solid Tumors | View Drugs | Massachusetts |
| Berzosertib | VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 | ATR kinase inhibitor |
|
| NCT03673124 | II | Low grade serous ovarian cancer | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum | View Drugs | Oklahoma |
| Letrozole | Femara | Aromatase inhibitor | | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor |
|
| NCT03461952 | II | Advanced solid tumors with POLE and/or POLD1 mutations | A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay | View Drugs | New York |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03776812 | II | Platinum resistant or refractory ovarian cancer | A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | View Drugs | Arizona, Illinois |
| nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | | Relacorilant | CORT125134 | GR antagonist |
|
| NCT03834220 | II | Advanced solid tumors with a FGFR1, FGFR2 or FGFR3 fusion | A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3 | View Drugs | Arizona, California, Florida, Louisiana, Maryland, Massachusetts, New Jersey, New York, North Carolina, Ohio, Texas, Washington, Wisconsin |
| Debiopharm 1347 | CH5183284, FF284, FGFR Inhibitor Debio 1347 | FGFR1-3 inhibitor |
|
| NCT03836352 | II | Recurrent ovarian cancer (with tumor lesions < 5 cm) | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours. | View Drugs | New York, Texas |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | DPX-Survivac | survivin antigen vaccine DPX-Survivac | Immune response against cancer expressing survivin | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03797326 | II | Advanced solid tumors | A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005) | View Drugs | California, Colorado, Tennessee, Wisconsin |
| Lenvatinib | Lenvima, ER-203492-00, E7080 | VEGFR1-3 kinase inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03868423 | II | Advanced solid tumors with ALK or ROS1 activating genomic aberrations | Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes | View Drugs | Ohio |
| Brigatinib | AP26113 | ALK and EGFR kinase inhibitor |
|
| NCT03697304 | II | Advanced solid tumors with prior PD-1/PD-L1 targeted treatment | An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy | View Drugs | California |
| BI 754091 | anti-PD-1 monoclonal antibody BI 754091 | Blocks PD-L1/2 inhibition of T cells | | BI 754111 | | Blocks LAG-3 inhibition of T cells |
|
| NCT02819843 | II | Advanced solid tumors - intratumoral injection | A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | View Drugs | New Jersey, New York |
| Radiation Therapy | Radiotherapy, Irradiation | | | Talimogene Laherparepvec | GM-CSF-encoding oncolytic herpes simplex virus, T-VEC | Induces immune response and tumor cell lysis |
|
| NCT03909152 | II | Recurrent PR+ low grade serous or granulosa cell ovarian cancer | Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer | View Drugs | New Jersey, New York |
| Onapristone ER | extended-release onapristone | PR antagonist that blocks PR activation and the associated expression of PR-responsive genes |
|
| NCT03935893 | II | Advanced solid tumors | A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers | View Drugs | Pennsylvania |
| Aldesleukin | | IL-2 receptor agonist | | Autologous TILs | | Anti-tumor immune response | | Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor |
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | View Drugs | Kentucky |
| Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
| NCT02710253 | II | Advanced solid tumors with progression on systemic immunotherapy | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | View Drugs | Texas |
| Radiation Therapy | Radiotherapy, Irradiation | |
|
| NCT03449108 | II | Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | View Drugs | Texas |
| Aldesleukin | | IL-2 receptor agonist | | Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | | LN-145 | autologous tumor infiltrating lymphocytes LN-145, autologous TILs LN-145 | Anti-tumor immune response |
|
| NCT03616834 | II | Advanced solid tumors with high MSI on checkpoint inhibitor treatment without evidence of complete or partial response | Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone | View Drugs | Arizona, California, Georgia, Idaho, Indiana, Maryland, Michigan, Ohio, Oregon, South Carolina, South Dakota, Texas, Virginia, Wisconsin |
| Tomivosertib | eFT508 | MNK1/2 inhibitor |
|
| NCT03861403 | Ib/IIa | Advanced solid tumors (inc ovarian expansion) | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | View Drugs | Florida, Indiana |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | TRX518 | anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518 | GITR (glucocorticoid-induced TNFR) agonist |
|
| NCT03684785 | Ib/II | Advanced solid tumors | A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors | View Drugs | California, Florida, Iowa, Massachusetts, Ohio |
| AST-008 | TLR9 agonist AST-008 | TLR agonist and immune cell stimulator | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03684811 | Ib/II | Advanced solid tumors with IDH1 mutations | A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | View Drugs | California, Florida, Iowa, Massachusetts, Michigan, Missouri, New Jersey, New York, Texas, Utah |
| FT-2102 | | mutated IDH1 inhibitor |
|
| NCT03601897 | Ib/II | Advanced solid tumors | An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors | View Drugs | Alabama, New York, Oklahoma, Pennsylvania, Tennessee, Texas |
| Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | Rebastinib | multitargeted tyrosine kinase inhibitor DCC-2036 | Multi-targeted kinase inhibitor |
|
| NCT02759588 | Ib/II | Platinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease) | Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15) | View Drugs | California, Florida |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | | GL-ONC1 | light-emitting oncolytic vaccinia virus GL-ONC1 | Membrane disrupter | | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT02785250 | Ib/II | Recurrent ovarian cancer | A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer | View Drugs | California, Georgia, New York, Oregon, Pennsylvania, Texas |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | DPX-Survivac | survivin antigen vaccine DPX-Survivac | Immune response against cancer expressing survivin |
|
| NCT02606305 | Ib/II | Advanced FRalpha+ ovarian cancer | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | View Drugs | Alabama, California, Massachusetts, Nevada, Ohio, Oklahoma, Pennsylvania |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Mirvetuximab Soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) |
|
| NCT02323191 | Ib | Advanced solid tumors (inc ovarian expansion) | Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid Tumors | View Drugs | Massachusetts |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | Emactuzumab | RO5509554, RG7155 | CSF1R antagonist and tumor-associated macrophage inhibitor |
|
| NCT02551185 | Ib | Advanced solid tumors | A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | View Drugs | Massachusetts |
| ACY-241 | HDAC inhibitor ACY-241, histone deacetylase inhibitor ACY-241 | HDAC inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT02419495 | Ib | Advanced solid tumors (in expansion) | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy Agents in Patients With Advanced Malignancies | View Drugs | Texas |
| Eribulin | B1939 mesylate, E7389, ER-086526, Halaven, halichrondrin B analog | Tubulin polymerization inhibitor | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Olaparib | AZD2281, Lynparza | PARP inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Selinexor | KPT-330, CRM1 nuclear export inhibitor KPT-330, selective inhibitor of nuclear export KPT-330 | Selective inhibition of nuclear export (SINE) |
|
| NCT03113188 | Ib | Advanced solid tumors | Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors | View Drugs | Arizona, Louisiana, Massachusetts |
| CBP501 | G2 checkpoint inhibitor CBP501 | G2 checkpoint inhibitor | | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03239145 | Ib | Advanced solid tumors (inc ovarian expansion) | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | View Drugs | Massachusetts |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Trebananib | AMG 386 | Angiopoietin 1/2 antagonist |
|
| NCT03099174 | Ib | Advanced solid tumors | An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts. | View Drugs | California, Connecticut, Florida, Minnesota, Nevada, North Carolina |
| Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | | Xentuzumab | BI-836845 | IGF-1/2 antagonist |
|
| NCT02994953 | Ib | Advanced solid tumors | A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors | View Drugs | California, Connecticut, Florida, Louisiana, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | NHS-IL12 | M9241, immunocytokine NHS-IL12 | IL-12 receptor agonist |
|
| NCT03611868 | Ib | Advanced solid tumors | A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors | View Drugs | Texas |
| APG-115 | MDM2-p53 inhibitor APG-115, p53-HDM2 protein-protein interaction inhibitor APG-115 | MDM2 inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03621982 | Ib | Advanced solid tumors (inc expansion) | A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors | View Drugs | California, Connecticut, New York, Tennessee, Texas |
| Camidanlumab Tesirine | anti-CD25-PBD antibody-drug conjugate ADCT-301, ADCT-301 | DNA damaging agent |
|
| NCT03650348 | Ib | Advanced HER2+ solid tumors (inc expansion) | A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors | View Drugs | California, Louisiana, New York, Texas |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | PRS-343 | anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343 | Immune response against cancer expressing HER2 |
|
| NCT03586661 | Ib | Recurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2-wild type)(inc expansion) | A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | View Drugs | Texas |
| Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | | Niraparib | MK4827, Zejula | PARP inhibitor |
|
| NCT03589651 | Ib | Advanced solid tumors (inc expansion) | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | View Drugs | California, Connecticut, Florida, Illinois, New Jersey, New York, North Carolina, Pennsylvania, Texas, Washington |
| Epacadostat | 3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360 | Inhibits IDO1 to stimulate immune response | | INCB050465 | PI3K-delta inhibitor INCB050465 | PI3K delta inhibitor | | MGA012 | anti-PD-1 monoclonal antibody MGA012, INCMGA00012 | Blocks PD-L1 inhibition of T cells |
|
| NCT02761694 | Ib | Advanced solid tumors with AKT1/2/3, PI3K, or PTEN mutations (in expansion) | A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN Mutations | View Drugs | Oklahoma, Tennessee, Texas |
| ARQ 751 | pan-AKT inhibitor ARQ 751 | Akt inhibitor | | Fulvestrant | Faslodex, ICI 182,780, ZD9238 | ER antagonist (SERD) | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT03558139 | Ib | Platinum resistant or refractory ovarian cancer (inc expansion) | A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy | View Drugs | Illinois, Michigan, Oklahoma, Texas, Washington |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | Hu5F9-G4 | anti-CD47 monoclonal antibody Hu5F9-G4 | Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis |
|
| NCT03318445 | Ib | Advanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion) | Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | View Drugs | California |
| Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
| NCT03260322 | Ib | Advanced solid tumors | A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | View Drugs | Arizona, California, Florida, Iowa, Kansas, Michigan, New York, Pennsylvania, Tennessee, Texas, Virginia |
| ASP8374 | PTZ-201 | Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03236935 | Ib | Advanced solid tumors with high MSI or dMMR | Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient Cancer | View Drugs | Texas |
| L-NMMA | pan-nitric oxide synthase inhibitor, NG-monomethyl-L-arginine | NOS inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03307785 | Ib | Advanced solid tumors | Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer | View Drugs | Arizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Niraparib | MK4827, Zejula | PARP inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | TSR-022 | | Blocks TIM-3 inhibition of T cells | | TSR-042 | anti-PD-1 monoclonal antibody TSR-042, ANB011, Dostarlimab | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03168061 | Ib | Advanced solid tumors | A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma | View Drugs | California, Indiana, Missouri, Nevada, New York, North Carolina |
| NC-6300 | epirubicin-incorporating micelle, epirubicin-conjugated polymer micelles, nanoparticle epirubicin, micellar nanoparticle-encapsulated epirubicin, K-912 | Topoisomerase II inhibitor |
|
| NCT03833427 | Ib | Advanced solid tumors | A Phase 1b Multi-center Clinical Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors. | View Drugs | California, Michigan, New Jersey, Texas |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Selumetinib | AZD6244, ARRY-142886 | MEK inhibitor |
|
| NCT03875313 | Ib | Advanced solid tumors | A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors | View Drugs | Texas |
| CB-839 | glutaminase inhibitor CB-839 | Glutaminase inhibitor | | Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor |
|
| NCT03449381 | Ia/Ib | Advanced solid tumors (inc expansion) | A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors | View Drugs | Connecticut, Florida, New York, Tennessee |
|
| NCT03514121 | Ia/Ib | Advanced solid tumors (in ovarian expansion) | A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors | View Drugs | Arizona, California, Connecticut, Illinois, Michigan, Oklahoma, Tennessee, Texas, Utah, Washington |
| FPA150 | anti-B7-H4 monoclonal antibody FPA150 | blocks B7-H4 inhibition of T cells | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03363776 | I/IIa | Advanced solid tumors | Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors | View Drugs | Arizona, California, Massachusetts, New York, South Dakota |
| BMS-986277 | | Undisclosed mechanism | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03110107 | I/IIa | Advanced solid tumors | Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors | View Drugs | Massachusetts, New Jersey, New York, Pennsylvania |
| BMS-986218 | | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02650986 | I/IIa | Advanced solid tumors (in expansion) | A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies | View Drugs | New York |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL | anti-NY-ESO-1 TCR gene-engineered lymphocytes | Immune response against cancer expressing NY-ESO-1 | | TGFbeta DNRII-transduced Autologous Tumor Infiltrating Lymphocytes | TGFbeta Dominant Negative Receptor II transduced TILS | TGFbeta ligand trap |
|
| NCT02913313 | I/IIa | Advanced solid tumors | Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors | View Drugs | New Jersey, New York, Pennsylvania, Utah |
| BMS-986207 | anti-TIGIT monoclonal antibody BMS-986207 | Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02754141 | I/IIa | Advanced solid tumors | A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors | View Drugs | Maryland, Massachusetts, New York, P |
